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Motivated by the biologically important and complex phenomena of Aβ peptide aggregation in 
Alzheimer’s disease, we introduce a model and simulation methodology for studying protein 
aggregation that includes extra-cellular aggregation, aggregation on the cell-surface assisted by 
a membrane bound protein, and in addition, supply, clearance, production and sequestration of 
peptides and proteins. The model is used to produce equilibrium and kinetic-aggregation phase 
diagrams for aggregation onset and of reduced stable Aβ monomer concentrations due to 
aggregation.  The methodology we implemented permits modeling of a phenomenon involving 
orders of magnitude differences in time scales and concentrations which can be retained in the 
simulation.  We demonstrate how to identify ranges of parameter values that give monomer 
concentration depletion upon aggregation similar to that observed in Alzheimer’s disease. We 
show how very different behavior can be obtained as reaction parameters and protein 
concentrations vary, and discuss the difficulty reconciling results of experiments from two 
vastly different concentration regimes. The latter is an important general issue in relating in-
vitro and mice based experiments to humans.  
PACS number(s): 87.18.Ed  02.50.Ey
I. Introduction 
Cooperative phenomena of biomolecules 
play many roles in living systems. One of 
the most important of these is protein 
aggregation into one-dimensional crystal-
like structures called amyloids. Such a 
crystalline state may be the most stable 
phase of generic peptides, but, if 
unregulated, can be harmful to living 
organisms through unanticipated gains of 
toxic function. In fact, many 
neurodegenerative diseases, such as 
Alzheimer’s and Mad Cow, are believed to 
be caused by the aggregation of certain 
proteins or their peptide fragments.  
In the case of Alzheimer’s disease (AD), 
one of the hallmarks of the disease is 
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abnormal accumulation of Aβ fibrils, 
aggregates of small peptide fragments 
called Aβ mostly found in extra-cellular 
space. At the same time, Alzheimer’s 
disease also gives rise to Tau-tangles, an 
aggregated state of the intracellular protein 
called Tau inside the cell. Some research 
suggests a connection between Aβ fibril 
formation and Tau-tangle formation [1,2]. 
In fact, there is a suggestion that the normal 
or cellular form of the mammalian prion 
protein PrPC interacts with Aβ [3-6] and may 
play a role in Aβ aggregate formation and 
its incorporation inside the cell [7-10], thus 
perhaps bringing it in contact with Tau 
proteins. Other reports, comparing mice 
with and without PrPC, suggest that PrPC has 
no effect on Alzheimer’s related 
aggregation [11,12]. There are several 
potential protein receptors whose 
internalization can bring Aβ aggregates 
along with them into the cell [13-15]. 
Several papers suggest that the Aβ might 
interact and alter the membrane cells 
secondary structure in a way that might 
form ion channels [16,17], we do not 
explore this model in this paper. 
We present and simulate a protein 
aggregation model that incorporates a 
coupling of Aβ-to a generic membrane 
bound protein receptor we denote PR.  
Thus we present a model, where there are 
competing pathways for aggregation of Aβ 
peptides. They can aggregate by themselves 
in the extra-cellular region or they can 
aggregate on a membrane bound PR 
protein. Many membrane bound proteins 
are known to be internalized into the cell by 
a process called endocytosis, a process of 
transporting proteins and molecules into 
the cell by engulfing them in a vessel that is 
encapsulated into the cell. Our model 
includes such intake of the membrane 
bound proteins into the cell. This intake 
may also bring the Aβ aggregates inside the 
cell, thus providing a mechanism for 
interaction between Aβ and Tau. Our paper 
focuses on understanding the conditions 
under which membrane bound receptor 
proteins such as PR play a substantial role in 
Aβ aggregation, and when their role 
becomes unimportant. In particular, we 
show that when Aβ concentration is large, 
the quantitative differences between 
having a membrane bound receptor protein 
present and absent can be masked. This is 
important from an experimental point of 
view, where in mice overexpressing Aβ, the 
difference in aggregation between those 
that had PR and those that didn’t, was 
found to be insignificant. The problem of 
mice models ability to be applicable in 
human is not unique to this aggregation 
model [18],   our method shows a way to 
scale data from mice to humans, where the 
concentration of Aβ is known to be 
substantially smaller.   
Processes like protein aggregation can 
be very complex and very sensitive to the 
conditions in the environment, with 
parameters such as initial concentration 
base production rate, and clearance rate 
affecting the aggregation outcome. (See 
Appendix for further discussion on our 
aggregation model parameter values.) 
Equations describing such reactions can be 
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non-linear and at times difficult to solve. 
Assumptions on concentration and reaction 
parameters can be used to simplify the 
equations in a way that make analytical 
solutions or simpler simulation possible, but 
when, for example, a phenomenon that 
may appear on time scale of years involves 
processes on a fraction of a second scale, it 
is not always clear how to simplify the 
model while keeping is viable and 
representative to the phenomenon in 
question. In this paper we demonstrate a 
way to investigate a complex protein 
aggregation process in a way that does not 
require simplifying the equations 
prematurely and thus allowing 
comprehensive exploration of the process 
in question. 
II. Models and simulations 
A. Aggregation model 
There already exist in the literature 
kinetic models for extra-cellular, free 
protein aggregation[19,20]. In several of 
those works, the total number of 
monomers or the monomer concentration 
is held constant. Our model expands the 
aggregation model to better represent in-
vivo systems and more accurately, to 
describe possible PR-Aβ interaction. In 
addition to allowing aggregates to attach 
and/or nucleate on those membrane-bound 
PR proteins, we consider an open system, 
allowing production or supply of free 
monomers of Aβ from outside the cell and 
PR from within the cell.  We allow 
extracellular clearance of Aβ monomers and 
aggregates, and clearance of PR and 
coupled Aβ-PR complexes through 
intracellular processes, in some aspects 
similar to process describe by Cisse et al [9]. 
We illustrate the processes in FIG. 1 and 
summarize the model reactions and 
parameter labels in Table I. 
 
FIG. 1: Illustration of the aggregation processes in a small volume around the neuronal surface. Single sided 
arrows represent attachment, double sided arrows represent detachment 
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Table I: Reactions and reaction constants: nf is the concentration of Free Aggregates (FA) of length
( 1)n n , 1f is the free monomers concentration, np  is the concentration of Membrane-Bound 
Aggregates (MBA) of length n  and 0p is the concentration of membrane proteins (PR). The reaction rate 
constants are: nk FA nucleation, Lk monomer attachment, BFk FA breakage, Lk monomer detachment,k
free monomers and aggregates clearance,k free monomer production, Ak single membrane protein – FA 
attachment, LMk monomer attachment to MBA, BMk MBA breakage, Lmk monomer detachment from 
MBA , Ak membrane protein – free aggregates detachment, nmk MBA nucleation, sr membrane proteins 
sequestration and pr is the membrane proteins production.
Our aggregation model is described 
by the set of reactions presented in Table I. 
The model includes nucleation of free 
aggregates from two free Aβ monomers (1). 
Once nucleated, aggregates can grow 
longer or get shorter by attachment or 
detachment of one Aβ monomer (2, 4), 
attachment from one side, detachment 
from both. When long enough, aggregates 
can break (3). We include Aβ production 
(6,7) and clearance of Aβ and free 
aggregates (5). Similar interactions are 
introduced for the membrane bound 
proteins (PR). Free aggregates can attach to 
a membrane protein (PR) to create a 
membrane bound aggregate (8). A single Aβ 
monomer can attach or detach to a 
membrane aggregate (9, 11). Membrane 
aggregates can break in two, a free 
aggregate and a membrane-bound one 
(10). Membrane bound aggregates can 
break free from the membrane; break from 
the PR (12). The PR can also induce 
aggregate nucleation, a process where two 
Aβ monomers join to a membrane PR to 
form a membrane bound aggregate (13). All 
reactions are assumed to be taking place in 
a reaction-volume outside the cell. The 
model includes production and clearance of 
PR (14,15, 16) into the reaction-volume, 
which we call production and 
sequestration. When PR is being 
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sequestered back into the cell while 
attached to an aggregate, the aggregate is 
also pulled into the cell and removed from 
the reaction-volume. We assume that the 
net flux of monomers in a given reaction 
volume is zero. We also assume that 
production and clearance of monomers is 
balanced when no aggregation occurs, so 
k  and k  are dependent as well as pr and sr  . 
The motivation for the model parameters 
values, used in our simulation are described 
in the appendix. 
B. Phase Diagram 
Our aggregation model has dynamical 
phases that can be characterized by 
different physical properties, such as 
aggregate concentration and sizes, the 
concentration of monomers and by the 
dynamical time dependent patterns of 
monomers and aggregates.  For example, 
there are phases: (i) Subcritical (S) with 
essentially no transient aggregation and 
unchanged monomer concentration 
changes. (ii) Aggregated (A) steady-state 
aggregation with monomer concentration 
reduced by a definite fraction. (iii) Transient 
Subcritical (TS) with observable levels of 
transient aggregates.   
Our goal is to explore the range of 
dynamical phases in the phase space 
determined by species concentrations and 
reaction parameters.    We have developed 
a computational algorithm to efficiently 
determine these phase diagrams. The 
details of the algorithm are provided in the 
appendix. In particular, we create phase 
diagrams for state A state, which represents 
a state with Alzheimer’s Disease (AD). 
C. Hybrid stochastic-deterministic 
study 
Due to the time scale differences 
between monomer production and the 
onset of AD we use a combination of 
stochastic and deterministic methods to 
computationally simulate the process and 
obtain the phase diagram for the system. 
We have used several sources [12,19] to 
guide us in choosing reaction parameter 
values, PR concentrations, and Aβ 
concentration but we modified those values 
according to the physical state we were 
exploring.    
The reactions in Table I give rise to a 
large set of nonlinear-coupled ordinary 
differential equations. In the model, the Aβ 
and PR concentrations can be very small 
and vary widely. Moreover, there can be 
many orders of magnitude difference in the 
values of reaction constants. An analytic 
solution that requires linearization and 
simplification of the equations is highly 
problematic if one do not want to risk losing 
important physical characteristics of the 
model. We will, instead, solve these 
equations by a predominantly stochastic 
numerical method, appropriate since some 
species have relatively small number of 
particles. 
The stochastic simulation of a chemical 
reactions set is based upon the probabilistic 
propensity of the reactions to occur and 
uses number of particles in a reaction 
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volume, not by concentrations. In our 
model, the monomer production and 
clearance reactions are far more likely to 
occur than any other reaction. Thus, a 
purely stochastic simulation will spend most 
of its time doing the trivial task of bringing 
monomers in and out of the system. Since 
the aggregation time can be of the order of 
years at low concentrations, including 
monomer supply and clearance as 
stochastic variables will make exploration of 
this model impractical. We therefore use a 
hybrid approach with aggregation and 
aggregate clearance reactions treated 
stochastically via Gillespie’s algorithm[21], 
and monomer creation and clearance 
treated deterministically.   The 
deterministic portion is designed in such a 
way that in the absence of aggregation one 
gets homeostasis of the monomers at 
values compatible with experimentally 
estimated concentrations.  
In the Gillespie method we use the 
probability distribution or propensity of 
each reaction to occur and stochastically 
choose the time till next reaction Gillespiedt  
and reaction type( ) . The Aβ production 
parameter k  and PR production 
parameter pr , were set according to k   
and sr , the clearance and sequestration 
parameters, in such way that a lack of 
aggregation will produce the desired stable 
concentration, ]( 0[ )tk A k   and 
[ ]( 0)p sr PR t r .We choose initial 
aggregate nucleation rate on the 
membrane to be comparable to free 
nucleation rate and use 2cn  (dimers) as 
the critical aggregate nucleus size. All 
concentrations were converted to number 
of particles.  All reaction parameters were 
converted to propensities according to the 
Gillespie method[21]. A concentration of ix  
was converted to number of particles using 
i A iX vN x , where v  is the reaction volume 
in liters and AN  Avogadro’s number .The 
Gillespie reaction parameters conversion 
method for the reaction in Table I is 
described in equations (1) to (3) using
AV vN . Quantities x  and y  in equations 
(1) to (3) are generic symbols for 
concentration of different species. 
 
;kix c k   (1) 
; /ki ix y c k V   (2) 
2 ; 2 /kix c k V   (3) 
The propensity for each reaction type to 
happen is c h  where c  is the converted 
reaction constant, and h  (Table II) is the 
number of ways a particular reaction can 
happen. In Table II, we denote the number 
of PR that are not attached to aggregates as 
0( )x t , the number of PR that are attached to 
an aggregates of length n  as ( )nx t , the 
number of free Aβ monomers as 1( )y t  and 
the number of free aggregates of length n  
as ( )ny t . 
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1 1 1( 1) / 2h y y  19 nh x y  
2 1 nh y y  10 ( 2) [ 1, 1]kh x k n m  
3 ( 3) [ , 1]kh y k n m  11 nh x  
4 2 [ 2]nh y n  12 nh x  
08 nh x y  13 0 1 1( 1) / 2h x y y  
Table II: Summary of ih , the number of ways reaction i can from Table I can occur, according to the 
number of particles involved in the reaction. ny is the number of free aggregates of length n . kx is the 
number of membrane bound aggregates of length k . 0x  is the number of membrane bound proteins 
without aggregates.
Noting the propensity for reaction as 
)( ha c  with (1, )M , and setting
0 1
M
a h c , using a random variable 1r , 
the time until the next reaction is  
0 1
1 1
ln( )Gillespiedt a r
 
 (4) 
The type of reaction is chosen based on 
the aggregates population, using the second 
random variable 2r  and the equation 
1
2
1 10 0
a a
r
a a  .
 (5) 
During the waiting time Gillespiedt  between 
the reactions, the monomers and only the 
monomers concentration, 1y  and 0x  
continues to evolve deterministically 
through their production and clearance. 
This is governed by the equation  
0
0
( )
( )p s
dx t
r x t r
dt
,  (6) 
With a solution  
0 0( ) (1 ) (0)s s
p r t r t
s
r
x t e x e
r
 . (7) 
Over the time Gillespiedt  it leads to the 
change  
0 0( ) (1 )
s Gillespier dtp
s
r
dx x t e
r
.  (8) 
The integer part of this change is added 
to 0x . The non-integer fraction is kept in a 
buffer and used in the next time-step. 
Equations (6,7,8) also apply to 1y with its 
corresponding production and clearance 
constants. 
 In the Gillespie method, after each 
reaction, the number of aggregates that 
were affected by the reaction is changed. 
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All relevant propensities are updated using 
those new numbers then the next time step 
and reaction are chosen using new random 
numbers. 
The aggregation onset time was 
evaluated in two different ways, the time 
till we have sustainable aggregates levels, 
aggregation and the time till the rate of the 
aggregation changes by a large factor over a 
set time. Aggregation transition time is the 
time between aggregation onset and the 
end stable state, when one exists. 
We tested our program successfully by 
comparing our aggregation results for no 
surface receptors and fixed monomer 
concentration to those presented in papers 
by Knowles et al[19] and Kunes et al[20]. 
 
III. Results 
We start by exploring states where the 
aggregation process can be sensitive to PR 
and other states where the PR impact can 
be missed. We explore how the kinetic 
diagram of the aggregation process may 
look like and how changing reaction 
parameter and nucleation characteristics 
might affect the aggregation kinetics. We 
then created phase diagrams for several 
concentration and reaction parameters. 
Table IV contains the reaction parameters 
values for all figures. 
 
FIG. 2: Critical aggregation phase transition due to changes in concentration. (a) no sustainable aggregation.  
(b,c) Critical behavior due to [ ]A . (e,f) Critical behavior due to [ ]PR . Blue (dash) line – Aβ monomers. Black (dash-
dot) line – PR/membrane bound aggregates. Green (solid) line – free aggregates. Reaction parameters are in Table IV. 
(a-c) initial[ ]A are 0.1nM, 0.11nM and 0.2nM respectively and [ ]PR are 2nM, 4nM and 10nM. In Plots (a), (e) and (f) 
The Aggregates concentration levels (black and green lines) are multiplied by 10.
FIG. 2 shows how sensitive the critical 
aggregation state can be. FIG. 2 (a) shows a 
state in the Subcritical phase; random 
aggregate concentration blips arise but fall 
back down to zero promptly. In FIG. 2 (b) a 
change of 0.01nM in the Aβ concentration 
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initiates aggregation (A phase). In FIG. 2 (c) 
we further increase the Aβ concentration. 
As expected, increase in the Aβ 
concentration shortens the aggregation 
onset time as well as increases the resultant 
aggregate concentration. Though 
quantifying onset time, aggregation levels 
and whether the aggregation levels are 
stable or not is not trivial and it depends on 
other model parameters 
Decreasing the Aβ concentration also 
increases the variation in the onset time. 
FIG. 2 (e) shows how changing the PR 
concentration can cause aggregation and in 
FIG. 2 (f) we see how higher concentration 
shortens the onset time and increases the 
aggregate levels. 
 
FIG. 3: PR effect on the aggregation process.  Blue (dash) [ ]A , Green (solid) [Free Agg.], Black (dot) [Membrane 
Agg.]. (a): Stable aggregates and [ ]A levels, [ ]PR is 8nM, (b): Without PR, (c): High Aβ concentration,[ ]PR is 0.8nM 
and (d): Without PR.
In FIG. 3 we explore the effect of 
eliminating PR from the reaction. FIG. 3 (a) 
shows a situation where we have both free 
aggregation and membrane bound 
aggregates; with time we see a reduction in 
Aβ monomer concentration level. FIG. 3 (b) 
shows how eliminating PR from the system 
hardly changes the total aggregate 
concentration, and only slightly affects the 
aggregation onset time. FIG. 3 (c) and FIG. 3 
(d) show a situation where the PR 
concentration is small compared to Aβ 
concentration. The system has many more 
free aggregates and thus elimination of PR 
and membrane aggregation has a small 
effect on the total aggregate concentration 
or the aggregation onset time. Both (c) and 
(d) show that eliminating the membrane 
aggregates increases the free aggregates. In 
(c) and (d) the Aβ monomers are nearly 
 10 | P a g e  
 
depleted after aggregation is stabilized. The 
Aβ level that is left at the end of the process 
is sensitive to the monomer attachment 
and detachment rates. High attachment 
and detachment rates can cause near 
depletion of   Aβ monomers from the 
system. 
 
FIG. 4: The effect of clearance rate on the aggregation kinetics. In all plots sk r (clearance = sequestration). 
(a,d): 0k . (b,e): 8 1101 sk , (c,f): 8 1105 sk . In plots (a-c) ] 0[ .2nA M ,[ ] 2PR nM . 
In plots (d-f) ] [ ] 2[ PR nA M . Blue (dash)[ ]A , Green (solid) [Free Agg.], Black (dot) [Membrane Agg.] 
FIG. 4 demonstrates time evolution of 
aggregate accumulation and how this 
evolution can be affected by varying the 
reaction parameters k and sr . We 
demonstrate how the increase of the 
clearance rate changes the characteristics 
of the process. The concentrations in (a-c) 
are representative of those in humans, with 
higher PR and lower Aβ levels. In (d-f) the 
Aβ concentration is elevated, to represent 
experimental conditions in mice. The 
aggregate levels change as the production 
and clearance rates change. In (c), the 
increased clearance rates prevent 
aggregation formation, in sharp contrast to 
the same rates at a higher Aβ concentration 
levels. The clearance rates had some 
influence on the onset time, though some 
variation is due to the stochastic nature of 
the simulation. 
When changing the relative clearance 
rates of aggregates and monomers, a 
slower clearance of aggregates and faster 
production of Aβ monomer causes 
accumulation of aggregates in the system. 
This effect is more pronounced in the 
situation with elevated Aβ monomer 
concentration.  
 11 | P a g e  
 
 
FIG. 5: Effect on aggregation kinetics of aggregate – membrane interaction propensity that is aggregate length 
dependent. In all plots 8 110sk r s , ] 0[ .2nA M and[ ] 2PR nM . (a): ( ) /A Ak n k n for 
aggregates of length larger than 10, (b): length independent Ak  and (c): ( )A Ak n nk for aggregates of length 
larger than 10. Blue (dash) [Aβ], Green (solid) [Free Agg.], Black (dot) [Membrane Agg.] 
This method allows exploration of 
aggregation model nuances; in FIG. 5 we 
explore how a membrane interaction 
propensity that depends upon oligomer size 
might affect the aggregation kinetics.  To 
simulate low propensity of large aggregates 
for membrane interaction, we change the 
propensity to attach to the membrane 
protein, so that for aggregate length n>10 
we reduce the attachment rate parameter 
to /A Ak k n  FIG. 5 (a).One might envision 
a situation where longer aggregates are 
slower to clear the system and more likely 
to get stuck on membrane proteins in a way 
that allows more time for those long 
aggregates to form bonds. To explore this 
scenario, we change the propensity of 
aggregates to attach to the membrane so 
that for aggregate length n>10 we have an 
attachment rate parameter of A Ak nk  
FIG. 5(c). The aggregation onset time 
appears shorter when there is no 
attachment length dependence FIG. 5 (b), 
slightly longer when we favor longer 
aggregates attachment and slightly longer 
when we penalize longer aggregates 
attachment. The difference in the onset 
time is not large and might be a result of 
the stochasticity of the process. The final 
concentration of Aβ monomers also 
appears to be similar in all plots. However, 
the amount of free vs. membrane 
aggregates is very different. When long 
aggregate attachment is favored, most 
aggregates end up attached to the 
membrane, while most aggregates are free 
of the membrane when longer aggregate 
attachment to the PR proteins is penalized. 
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FIG. 6: Critical aggregation transition phase line. (a): [ ]A  vs. [ ]Ak , (b):[ ]A vs. [ ]BFk , (c):[ ]A  vs. [ ]PR , (d):
[ ]A  vs. [ ]k . Above the phase line aggregates are formed, under the line there is no sustainable aggregation. 
Reaction parameters in Table IV 
 
 
FIG. 7: 40% [ ]A stable level reduction phase line. (a): [ ]A  vs. [ ]Ak , (b): [ ]A vs. [ ]BFk , (c):[ ]A  vs. [ ]PR , 
(d):[ ]A vs. [ ]k . Above the phase line [ ]A higher than 40%, under the phase line it is lower. Reaction parameters in 
Table IV 
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In FIG. 6 and FIG. 7 demonstrate 
investigation of two phenomenon’s, critical 
aggregation and a process of aggregation 
that ends at reduced stable Aβ levels, we 
set initial [Aβ] and run the model, the [Aβ] 
is not held at the initial level, but is allowed 
to fluctuate according to the model. Those 
figures demonstrate phase diagrams for 
[ ]A  vs. [ ]Ak (a) , [ ]A  vs. [ ]BFk  (b), [ ]A  vs. 
[ ]PR  (c) and [ ]A  vs.  [ ]k  (d) for the two 
example process, 40% reduction and  stable 
level of [Aβ] state and the critical 
aggregation state. In addition to showing 
the relation between the reaction 
parameters, the phase diagrams  reveals 
non-trivial relations of the phase boundary, 
in that aggregation no-aggregation 
boundary can be at different monomers 
concentration when following different 
reactions parameters, or that a particular 
phenomenon might not realistically exist for 
some values of reaction parameters . The 
phase diagrams also show that there is 
some initial Aβ concentration above which 
aggregation always happens and above 
which the Aβ concentration ratio observed 
between healthy human and AD patients 
might not be attainable. Simulations with 
different reaction parameters produced 
different phase curves. We fitted different 
curves types to the phase diagrams. We 
denote rational fit curves with RAT, power 
fit with POWER and exponential fit with 
EXP. RAT, POWER and EXP curves are 
defined in equations (9),(10),  (11) and (12). 
The parameters for the different figures 
fitted curves are in Table III. 
2
1 2 3
2
0 1 2
RAT
p x p x p
y
q x q x q  
 (9) 
1
1 2
q
POWERy p x p   (10) 
2
1 2 3POLY p x p py x   (11) 
1 1 2exp( 2 exp() )EXP p xy p qq x   (12) 
 
 Fit function p1 p2 p3 q0 q1 q2 
FIG. 6(a) RAT 0 0.09 0.19 0 1 1.66 
FIG. 6(b) RAT 0 0.055 0.134 0 1 0.632 
FIG. 6(c) RAT 0 0.087 0.437 0 1 3.962 
FIG. 6(d) RAT 2488 1580 17 1 39540 78 
FIG. 7(a) EXP 0.23 -0.65   1.57 -0.006 
FIG. 7(b) POWER 11 0.0   -1  
FIG. 7(c) RAT 0 1.39 0.95 0 1 0.53 
FIG. 7(d) POLY 0.04 005 0.08    
Table III: Fitting parameters for equations (9,10,11), FIG. 6 and FIG. 7 
In FIG. 6 we evaluate the critical 
aggregation by looking at the average 
amount of aggregate over time and by the 
aggregation sustainability. Two interesting 
phenomenon can be observed, the first, 
since our model does not enforce total 
number of monomer in the reaction 
volume. Since the clearance and creation of 
monomers are related to each other and to 
the initial Aβ levels, and the clearance rate 
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of Aβ monomers is the same as 
clearance rate of free aggregates, at a 
slow monomers creation and 
clearance rate the clearance of 
aggregates  can reduce significantly 
the number of  Aβ in the system and 
may create non-monotonic behavior 
as observed in FIG. 6.(d) .Another 
observation is that when the Aβ level 
is low and the PR is high, the 
stochastic variability is very large, 
aggregation become Subcritical, 
where no aggregation occurs, 
Transient Subcritical, where 
aggregation forms but does not last in some 
osculating manor, and the critical 
aggregation line becomes blurred and hard 
to determine.  A particular range of Aβ 
concentration, production rate and 
corresponding sequestration rate is needed 
to make for a clear distinct appearance of 
the critical aggregation line. This 
phenomenon is very visible in FIG. 6.(d) but 
when producing FIG. 6 (a) and (b) that 
tendency was visible and was more 
pronounced at higher values ofk and BFk .  
 
 
FIG. 8: Onset time distribution histogram with a 
generalized extreme value (GEV) distribution fit. GEV 
probability function parameters:  k (Shape) = 0.3165, σ 
(Scale) = 0.4129 and μ (Location) = 0.7790, at 95% 
confidence level. GEV typically used for assessing various 
financial risks and phenomenon with extreme deviation 
from the median of event probability distribution. 
The stochastic variability of the 
aggregation onset time increased as the 
number of particles in the simulation 
volume decreased. FIG. 8 shows the onset 
time distribution for the simulation with 
parameters adapted for humans, using the 
parameters in the last column in Table IV 
and with 1,000 iterations. 
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Reaction parameters 
 
Critical aggregation  
FIG. 2 
PR indifference  
FIG. 3 
Production rate and 
aggregation kinetic  
FIG. 4 
Critical 
aggregation 
FIG. 6 
%40 reduction  
in Aβ Levels 
 FIG. 7, 8 
a-c e,f a,b c,d a-c d-f State point State point 
1 1( )Lk M s   1500
 1500 1500 1500 1500 1500 1500 1500 
8 11( )0Lk s   3
 3 3 3 3 3 3 3 
1 1( )LMk M s   1500 1500 1500 1500 1500 1500 1500 1500 
8 110( )LMk s  3 3 3 3 3 3 3 3 
11( )Ak M s  100 100 100 100 100 100 100 100 
181( )0Ak s  50
 50 50 50 50 50 50 50 
1 1510( )nk M s  9.5
 9.5 9.5 9.5 9.5 9.5 9.5 9.5 
1810( )BFk s  0.15
 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
1810( )BMk s  0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
( )A nM  Vary 0.1 0.8 0.8 0.2 2 0.1 0.17 
( )PR nM  2 Vary Vary Vary 2 2 2 2 
1810( )sr s  1 1 1 1 Vary Vary 1 1 
18( )10k s  1 1 1 1 Vary Vary 1 1 
Table IV: Reaction parameter values for the simulations presented in this paper. See Appendix for experimental values. 
IV. Discussion  
In this work, we have developed a 
model for aggregation that includes extra-
cellular and membrane-assisted 
aggregation as well as mechanisms for 
supply and clearance of monomers and 
aggregates. Using a hybrid stochastic-
deterministic method we were able 
simulated complex aggregation process 
without the need to simplify it, keeping 
non-linear relations and parameters with 
orders on magnitude values differences. 
The Gillespie method was used for the 
aggregation reactions and a deterministic 
method for the monomers supply and 
clearance. Examining the aggregation 
kinetics and the effects of different reaction 
parameters on it, we identified critical 
conditions for onset of aggregation, 
conditions that produced stable levels of 
aggregates and Aβ; and conditions where 
once aggregation started the amount of 
aggregates increased with time. For such 
states we obtained appropriate phase 
diagrams. 
In the context of phenomenon that 
might not be observed in mice but might 
still be important in human, we observed 
that several of the reaction parameters and 
concentration can have a significant effect 
on the aggregation onset time, aggregate 
levels, and on whether aggregation will 
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occur or not. In some of the states that we 
explored, we observed that the initial Aβ 
and PR concentration levels and the 
corresponding monomer production rates 
can have significant effect on the 
aggregation process, while at high levels of 
Aβ we observed that the PR contribution to 
the total amount of aggregates can be 
small. The critical line between states with 
no time averaged aggregates and states 
with steady state aggregates, as well as 
some states of stable aggregation were 
inaccessible under those high [Aβ] 
conditions. At lower levels of Aβ and PR we 
observed high sensitivity of the aggregation 
process to concentration changes.  
We observed that clearance and 
production rates can dramatically change 
the characteristic of the aggregation 
kinetics (FIG. 4). Clearance and production 
rate can affect the levels of monomers and 
aggregates, whether the level of aggregates 
is stable or continuously rising, the 
aggregation onset time, and can even 
determine if aggregation will happen at all. 
Attachment and detachment rates of 
monomers to aggregates and the ratio 
between them also affected the end level of 
Aβ monomers and the aggregation 
transition time. A high attachment-to-
detachment rate ratio meant that almost all 
monomers would attach to some aggregate 
as soon as they enter the system. High 
values of those rates meant that the 
aggregation transition time was shorter. 
The ratio between the free nucleation and 
the membrane assisted nucleation was also 
important to the role of the PR. In this 
paper we only show results where the free 
and membrane assisted nucleation were 
comparable. We also observed that the 
smaller the number of particles in our 
system, the greater the fluctuation in 
aggregation onset time and the smaller the 
maximum size of aggregate. 
The number of particles in the system is 
a consequence of the concentration and the 
reaction volume. The reaction volume 
should represent the physical dimension of 
the brain and the relevant neuronal 
environment where the aggregation takes 
place. In our simulations, the number of 
particles in the system was in the range of 
hundred thousand to millions, which we 
believe are reasonable numbers for in-vivo 
simulation. With those particle numbers 
and the reaction parameters we used, the 
maximum aggregates length we needed to 
use was 500–800.  
Reported Aβ levels 
Heathy human CSF Aβ42 700(250) pg/mL 
Human with AD CSF Aβ42 451(178) pg/mL 
Human with AD Soluble Aβ 8.6±2.1 pmol/gr 
Mice Soluble Aβ 1629 ± 380 pmol/gr 
PrPC cell-surface expression 
Human 6H4/Blood PLT Cell 619 ± 167 
Mouse 6H4 /Blood PLT Cell 5 ± 3 
Table V: mean (standard deviation) of CSF Aβ42 in healthy 
and human with AD [22,23]. Soluble Aβ40 and Aβ42 levels 
as reported for a APP/PS1 mouse model of AD and 
Humans [24]. Expression of cell-surface PrPC, measured as 
the number of anti-prion mAb 6H4 molecules bound per 
blood cell in human and mouse platelets (PLT) [25,26] 
In human AD it’s reported that Aβ levels 
in healthy people are about 40% higher 
than that of AD patients[22,23,27] and that 
the levels of aggregates in AD patients does 
not increase with time[28-30].  We 
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examined a phase state that has those 
features and found that this state is not far 
above the critical aggregation state in terms 
of Aβ levels (In Table III the parameters for 
FIG. 6 and FIG. 7 show 0.07nM difference 
between those states). This means that our 
model supports a scenario in which 
increased level of Aβ can trigger an 
aggregation process that ends in the 
experimentally observed Aβ and aggregate 
levels state.  
There are conditions in mice 
experiments that are different than those of 
human and that can be accounted for in our 
model. The Aβ concentration can be many-
fold larger in mice[24] (Table V), and 
clearance and production rates can be very 
different than those in humans. Indeed it 
appears that aggregate levels increase with 
time[31] ,and possibly the secondary 
structure of the aggregates is suspected to 
be different[24]. We showed how the 
formation of Aβ aggregate can be, both 
sensitive and indifferent to PR presence 
depending on parameters. FIG. 2 
demonstrated how small increases in PR 
levels can initiate aggregation. On the other 
hand, FIG. 3 shows how the effect of the PR 
can be missed, either because the total 
amount of aggregates in the system remain 
the same, or due to much higher Aβ levels 
that result in free aggregation dominating 
the process. FIG. 6 reveals that above some 
Aβ concentration level aggregation will 
always happen, and that we might lose 
sensitivity to other reaction parameters 
effects on aggregation. 
The kinetic diagram (FIG. 4) can be an 
important link between experiments and 
our model, since the kinetic diagram can be 
constructed experimentally by measuring 
monomer and aggregate levels. Additional 
links between experiments and our model 
can be the length of aggregates found in 
mice or humans, the fluctuation in 
aggregation onset time, the aggregation 
transition time and the relevant reaction 
volume in the brain where the aggregation 
takes place. The kinetic diagram can also be 
used to explore nuances in the aggregation 
model as demonstrated in FIG. 5, where we 
looked at the dependence of membrane 
attachment propensity on oligomer size.  
Our model includes sequestration of PR-
Aβ aggregates; it can give estimated 
amounts of Aβ aggregates in the cell as a 
function of time. This information can be 
very useful when exploring the relations 
between the Alzheimer’s Aβ fibrils and Tau 
tangles and the mechanisms by which the 
Aβ fibrils could promote Tau tangle 
formation. 
The phase diagrams are new useful 
tools produced by our model and 
simulation. A tool to compare and interpret 
phenomenon that happens in different 
environments.  Once the phase diagrams 
for a particular phase state in humans are 
known, they can give insight into the 
concentration levels and reaction 
parameter values that should produce a 
similar state in mice, and help design and 
interpret experiments. The phase diagrams 
can also provide a link between different 
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mice experiments and may help gain 
knowledge on the values of reaction 
parameters, including breakage rates, 
attachment rates, nucleation rates and so 
on, that are not known. 
The median of the aggregation onset 
time, the time in which the aggregation rate 
increases significantly and after which the 
system contains sustainable elevated 
amount of aggregates, as describe in right 
skewed FIG. 8, and FIG. 5 (b) is about 26 
years. The aggregation transition time, FIG. 
5, have about the same scale, which make 
the time scale of 54 years FIG. 5 (b) or 69 
years FIG. 5 (c), years to get to a stable AD 
like aggregation levels  
 
The hybrid stochastic-deterministic 
method, provides a powerful ability to 
simulate very different reaction parameters 
scales. Perhaps an improvement to this 
method can made by switching to a pure 
stochastic model when the production and 
clearance time scales becomes similar to 
the Gillespie time steps. In particular in 
phase exploration such as in Fig 6 and 7, 
some behavior might have been affected 
hybrid stochastic-deterministic model. 
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VI. Appendix 
A. Reaction and simulation 
parameters 
The reaction parameters in our model 
are not well known, but some of the 
aggregation physical traits are known to 
some degree. The concentrations of Aβ and 
PR, though not uniform in the brain, are 
known at a coarse grained level. We know 
the AD aggregation time characteristics, 
decades for aggregation onset time and 
several years for aggregation transition. We 
also wanted to reproduce the observed 
reduction in Aβ monomers levels and the 
stable or slowly growing amount of 
aggregates in AD patients. We considered 
equal, free and membrane, initial 
nucleation rates and assumed that the 
concentration of Aβ is lower than that of 
PR. The volume we used in our simulation 
was 1015nm3, the volume unit is such that 
concentration of 2nM gives about 106 
particles. This volume represents the region 
between neurons, where the aggregation 
takes place. A human brain volume is about 
1.2 liter and contains about 0.14 liter of 
cerebral fluid. There are about 85 billion 
neurons in a human brain. This implies that 
there are about 600 neurons in and around 
our reaction volume. 
The larger the number of particles in a 
system, the larger the maximum length of 
aggregate we need in the simulation. The 
reaction parameters and clearance rate also 
affect the aggregate size distribution and 
maximum aggregate size. We set this at 500 
and monitored the simulation, to ensure 
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that there were no aggregates exceeding 
this length. 
Aβ production is such that about 7% of 
total number of particles are being 
produced every hour[32,33]. In the absence 
of aggregation, the production and 
clearance are assumed to be at 
homeostasis. This gives us 12[ ]k s  and 
1512 [ ]0k s   which implies a residence 
time of the order of several hours 1 / k . 
We took the residence time of a PR on the 
cell membrane to be about 11 hours 
(40000s). This gives
1 5 1140000 [ ] 10 [ ]2.5sr s s , a rate 
equivalent to that of the Aβ. Those 
production and clearance rates are so fast 
that in order to achieve the desired 
aggregation onset time and the observed 
Aβ levels, the aggregation transition time 
must be in the order of days or else 
aggregation will never happen. Since we 
believe that aggregation transition time is in 
the order of years, we believe these rates 
represent effective clearance, modified 
from the dictates of estimated production 
rates and concentrations due to the 
heterogeneous character of Aβ production 
in the brain or by biological processes 
omitted from our simple model. While most 
aggregates and monomers are being 
produced and cleared at fast rates, some 
are in the system for a longer period of 
time. Those aggregates and monomers are 
the important ones for the aggregation 
process. We chose those effective rates in a 
way that reproduced the observed 
experimental data and gave slow transition 
times that compare well with observed 
onset times for disease.   
The rest of the reaction parameters were 
adjusted in a way that the desired physical 
phase characteristics were reached. 
B. Phase Diagram Exploration 
Method:   
We explore the dependence of several 
state phases of the aggregation system 
upon our model parameters. First we 
examined the state with a stable final Aβ 
monomer concentration that is 60% of the 
initial concentration, reflecting the 
experimental data for Aβ levels in healthy 
humans and those with AD [22,23,27]. 
Second, we determine the critical boundary 
between a state with no significant long 
time average aggregate, and those for 
which steady aggregation is achieved [34-
36]. Initial parameters used for those 
phases are given in Table IV. 
Once a phase state point was found, we 
chose two of the reaction or concentration 
parameters we want to draw a phase 
diagram for.  We create the phase diagram 
by changing one of the parameters, and 
adjusting the second parameter in a way 
that puts us back on the phase line. We 
record the new point and continue to the 
next one. For example, in the phase state of 
40% change in Aβ levels, changing one 
reaction parameter might cause a final Aβ 
level to change by only 39%, so we will need 
to adjust the second parameter to bring it 
back to 40%. Note that while along the 
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phase line the particular chosen property is 
being maintained, other physical properties, 
like the aggregation onset time, might 
change. 
The algorithm we developed to 
automate this search utilizes 4 parallel 
processes to follow the phase line. The 
phase boundary line is approximated as 
linear, at a small enough distance near the 
known state point. The linear phase line 
intersects a half circle curve, in the 
parameter space, at that small radius 
around that point. To find the intersection 
point we divide the half circle with sub-
regions. Each processor runs a simulation 
for a sub-region. The result of the 
simulations indicates the region in which 
the solution lies. We then divide the 
solution region to smaller sub-regions and 
repeat the process until we are sufficiently 
close to the phase line separating distinct 
behavior. Once several points on the phase 
diagram are known, we can use a projection 
of the phase line to increase the step size 
between points. We use different random 
number streams for each run. The 
exploration process can be run in both 
varying parameter directions. 
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